Supplemental File 4.

Meta-regression results for various analysis strata

BCVA	Multivariable regression
	Beta	95% CI	P
BCVA 12 months
Dosing schedule	−1.97	−3.82 - −0.12	<0.0001
Design (RCT vs. non-RCT)	1.85	−5.37 - 9.07	0.589
Sample size	−3.44	−9.03 - 2.16	0.207
BCVA 24 months
Dosing schedule	−3.17	−3.93 - −2.40	<0.0001
Design (RCT vs. non-RCT)	N/A	N/A	N/A
Sample size	N/A	N/A	N/A
BCVA all studies (all follow-up times)
Dosing schedule	−2.4	−3.38 - −1.42	<0.0001
Design (RCT vs. non-RCT)	1.4	−3.75 - 6.55	0.58
Sample size	−3.35	−7.41 - 0.71	0.102
CMT 12 months
Dosing schedule	31.5	13.31 - 49.61	0.002
Design (RCT vs. non-RCT)	39.6	−24.4 - 103.5	0.206
Sample size	23.9	−28.6 - 76.29	0.346
CMT 24 months
Dosing schedule	35.6	26.3 - 50.9	<0.0001
Design (RCT vs. non-RCT)	N/A	N/A	N/A
Sample size	N/A	N/A	N/A
CMT all studies (all follow-up times)
Dosing schedule	30.45	17.7 - 43.24	<0.0001
Design (RCT vs. non-RCT)	19.3	−36.1 - 74.7	0.477
Sample size	9.25	−35.47 - 53.99	0.672

For the above analysis strata, the restricted maximum likelihood estimate of between-study variance (tau2) and joint test for all covariates with Knapp-Hartung modification are statistically significant (P=0.002-P <0.0001). All Betas are adjusted for other variables in each analysis strata. N/A: Not applicable, unable to estimate due to multi-collinearity or small number of studies, CI: Confidence interval, BCVA: Best-corrected visual acuity, RCT: Randomized clinical trial, CMT: Central macular thickness